SCHEMBL6989840

SCHEMBL6989840

CCOC(=S)c1ccnc(C)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.37
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 4/20 0.34
HPGD P15428 3/20 0.34
PIK3C3 Q8NEB9 1/20 0.32
CDC7 O00311 2/20 0.32
DBF4 Q9UBU7 2/20 0.32
NUDT1 P36639 1/20 0.32
HSD17B10 Q99714 2/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
POLB P06746 1/20 0.31
GRM4 Q14833 1/20 0.31
LMNA P02545 2/20 0.30
MAPT P10636 1/20 0.30
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA9 Q16790 1/20 0.30
HTT P42858 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7068952 0.81 ALDH1A1 (0.33) ALDH1A1KDM4EPIK3C3KMT2ASMN1; SMN2
SCHEMBL30625833 0.79 CYP1A2 (0.37) CYP1A2ALDH1A1KDM4EHPGDPIK3C3
SCHEMBL4745019 0.75 GRM4 (0.39) ALDH1A1KDM4EPIK3C3KMT2ASMN1; SMN2
Potassium SCHEMBL6986956 0.73 GRM4 (0.38) ALDH1A1KDM4EPIK3C3KMT2ASMN1; SMN2
SCHEMBL20267525 0.71 CYP1A2 (0.49) CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL11451174 0.70 CYP1A2 (0.35) CYP1A2ALDH1A1KDM4EPIK3C3KMT2A
SCHEMBL8887619 0.69 BAZ2B (0.50) CYP1A2KDM4EHPGDCDC7DBF4
SCHEMBL20892736 0.68 KMT2A (0.59) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL9684348 0.68 RAB9A (0.37) ALDH1A1KDM4EHPGDKMT2ASMN1; SMN2
SCHEMBL24271104 0.68 KDM4E (0.33) KDM4EGRM4LMNACYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107286135-B Heterocyclic compound with Wnt signal channel inhibition activity and application thereof 苏州云轩医药科技有限公司 2020-08-04 CN disclosed
US-6570015-B2 Reacting alpha-keto ester with an isothiourea UBE INDUSTRIES, LTD. (JP) 2003-05-27 US disclosed
US-20030055252-A1 Process for producing 2-substituted thiopyrimidine-4-carboxylate UBE INDUSTRIES, LTD. (JP) 2003-03-20 US disclosed
EP-1093367-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-03-05 EP disclosed
EP-1079821-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2001-08-29 EP disclosed
EP-1093367-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-04-25 EP disclosed
EP-1079821-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-03-07 EP disclosed
WO-1999066925-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-12-29 WO disclosed
WO-1999059570-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055252-A1 Process for producing 2-substituted thiopyrimidine-4-carboxylate DHFR, TYMS, DPYD CYP1A2 59/4885ALDH1A1 273/4885KDM4E 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.